Acción 300685 AMOY DIAGNOSTICS CO., LTD.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Amoy Diagnostics Co., Ltd.

Acciones

300685

CNE1000034D3

Precio de cierre Shenzhen S.E.
Otros sitios de cotización
 00:00:00 26/04/2024 		Varia. Cinco días. Varia. 1 de enero.
21,55 CNY +2,13 % Gráfico intradía de Amoy Diagnostics Co., Ltd. +2,13 % -1,96 %
22/04 Amoy Diagnostics Co. informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024 CI
15/04 Amoy Diagnostics Co. Ltd. presenta los resultados del ejercicio cerrado el 31 de diciembre de 2023 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Amoy Diagnostics Co., Ltd. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 26, 2024.
Amoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component A Share Index
Amoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component Index
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Amoy Diagnostics to Collaborate with AstraZeneca Unit for Ovarian Cancer Companion Diagnostic in China
Amoy Diagnostics Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023
Amoy Diagnostics Co., Ltd. Approves Final Dividend for 2022
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Amoy Diagnostics Co., Ltd. Proposes Final Cash Dividend for the Year 2022
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for selpercatinib RET fusion positive NSCLC
Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. and Precision Medicine Asia Co., Ltd. Announces the Japanese Ministry of Health, Labour and Welfare Approval in Japan as a Companion Diagnostic for Ret Fusion-Positive NSCLC
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022.
Amoy Diagnostics Co., Ltd.'s Equity Buyback announced on February 13, 2023 has expired with 3,943,726 shares, representing 1% for CNY 112.01 million.
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022.
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022.
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción 300685
  4. Noticias Amoy Diagnostics Co., Ltd.
  5. Otros idiomas